Sarafan ChEM-H 10-Year Report (2013-2023)
Building a Foundation to propel innovation
Reflecting on the first decade of Sarafan ChEM-H
"Sarafan ChEM-H benefited from the support of two university administrations and two Deans of Research; the leadership of two different faculty directors; and the opportunity to launch both the Stanford Innovative Medicines Accelerator (IMA) and the Stanford Microbiome Therapies Initiative (MITI). Our strength lies in our response to a changing world: recognizing and embracing change, identifying the role we can and should play, and rallying people and resources around a shared vision. The transitions we have lived through highlight not only the strength of Sarafan ChEM-H but the necessity of Sarafan ChEM-H; the more we understand about the molecular basis of health and disease and the better we learn to engage deeply across disciplinary boundaries, the more prepared we will be to respond to emerging diseases and any challenge to human health."
Elizabeth Ponder
Executive Director of Sarafan ChEM-H